Teva seeks to raise up to $25 billion in bond sale to finance Allergan deal

Teva Pharmaceutical Industries (NYSE: TEVA) will raise between $20 billion and $25 billion in a multi-currency bond sale to pay for its $40.5 billion acquisition of the generics business of Ireland-incorporated company Allergan (NYSE: AGN).

Reports said that the Israeli generics giant was hoping to raise this sum in the next week, having disclosed its intentions in a US Securities and Exchange Commission filing.

Calls are taking place with investors across the world to finance what is a complex takeover of the Allergan unit, particularly due to the conditions placed on the deal to prevent the merged entity from breaching competition rules.